Can brachytherapy spread prostate cancer?

In an earlier commentary (see this link), we looked at the available evidence that invasive procedures, including surgery, biopsy, and brachytherapy, could spread prostate cancer. … READ MORE …

Nadir PSA predicts survival after radiation and androgen deprivation for unfavorable risk patients

The following commentary addresses the article on risk for recurrent prostate cancer that we had mentioned briefly yesterday.

If a treatment isn’t working, we want to know as quickly as possible so we can try a salvage therapy while it can still make a difference. … READ MORE …

A possible new opportunity for treatment of advanced, neuroendocrine forms of prostate cancer?

An article by Strosberg et al. in today’s issue of the New England Journal of Medicine has nothing to do with prostate cancer at all; it’s all about a new form of treatment for certain types of advanced midgut cancer — but … READ MORE …

Letters to the Editor on interpretation of data from the ProtecT trial

In September last year, Hamdy et al. published the initial results of the ProtecT trial — a trial designed to compare overall outcomes at 10 years among > 1,600 men diagnosed with low- and intermediate-risk, localized prostate cancer and randomized to treatment by surgery, by external beam radiation therapy, or by active monitoring (a very basic form of active surveillance). … READ MORE …

Treating metastatic prostate cancer in very elderly men: a review

A helpful review article on the treatment of metastatic and metastatic, castration-resistant prostate cancer (mCRPC) in very elderly men appears in last month’s issue of Clinical Interventions in Aging. … READ MORE …

Population-based rates of treatment for prostate cancer: 2007-2012

The population-based rate of Medicare patients getting treatment for prostate cancer dropped by 42 percent from 2007 to 2012 … but this drop did not occur in patients who had a high risk of dying from a cause other than prostate cancer within 10 years, who are arguably among those who least need immediate treatment for prostate cancer (and especially for low-risk forms of prostate cancer). … READ MORE …

Incidence, outcomes, ethnicity, and distant, de novo, metastatic prostate cancer

Diagnosis of men with distant, metastatic prostate cancer at first presentation (distant, “de novo”, metastatic prostate cancer) is a lot less common today than it was 30 or 40 years ago, but it does still happen on a regular basis. … READ MORE …